human
respiratori
syncyti
viru
hrsv
major
caus
pediatr
infect
also
caus
diseas
elderli
underli
respiratori
problem
vaccin
hrsv
antivir
therapeut
broadli
applic
investig
effect
hrsv
biolog
children
nasopharyng
aspir
taken
children
differ
viral
load
combin
high
throughput
rnaseq
label
free
quantit
proteom
approach
use
character
nucleic
acid
protein
sampl
hrsv
protein
identifi
nasopharyng
aspir
infect
children
abund
correl
viral
load
ct
valu
confirm
hrsv
infect
analysi
hrsv
genom
indic
children
infect
subgroup
viru
minor
variant
nucleotid
frequenc
occur
discret
cluster
along
hrsv
genom
within
patient
cluster
distinctli
within
glycoprotein
gene
data
sampl
bin
four
group
nohrsv
infect
control
high
viral
load
ct
medium
viral
load
ct
low
viral
load
ct
cellular
protein
associ
antivir
respons
eg
identifi
nasopharyng
aspir
abund
correl
viral
load
combin
approach
use
studi
hrsv
biolog
vivo
readili
appli
studi
variat
viru
host
interact
tabl
anova
comparison
abund
author
contribut
conceptu
wa
jah
methodolog
wa
dam
nyr
sa
softwar
wa
dam
formal
analysi
wa
gp
nyr
sa
resourc
ecg
data
curat
sa
writingorigin
draft
prepar
wa
jah
writingreview
edit
author
supervis
jah
ot
project
administr
wa
jah
fund
acquisit
wa
jah
human
respiratori
syncyti
viru
hrsv
one
major
lower
respiratori
tract
pathogen
infant
consist
annual
outbreak
infant
infect
hrsv
least
within
first
two
year
life
elderli
patient
patient
chronic
heart
lung
condit
asthma
immunocompromis
patient
also
risk
sever
infect
subsequ
diseas
coinfect
respiratori
pathogen
may
exacerb
clinic
symptom
accord
world
health
organ
approxim
million
peopl
infect
hrsv
associ
death
everi
year
hrsv
exist
two
distinct
lineag
known
subgroup
b
repres
two
line
diverg
evolut
genet
serolog
differ
subgroup
b
virus
contribut
overal
hrsv
diseas
studi
suggest
subgroup
isol
may
slightli
differ
clinic
present
effect
host
cell
signal
compar
subgroup
b
virus
contrast
studi
found
differ
sever
ill
caus
either
subgroup
howev
subgroup
clade
viru
shown
associ
sever
ill
subgroup
clade
hrsv
belong
genu
pneumoviru
famili
paramyxovirida
order
mononegaviral
viral
genom
consist
nonseg
rna
neg
polar
encod
protein
member
mononegaviral
genom
rna
hrsv
alway
tightli
bound
viral
nucleoprotein
n
maintain
helic
nrna
ribonucleoprotein
rnp
complex
rnp
use
templat
transcript
replic
viral
mrna
genom
rna
rnadepend
rna
polymeras
rdrp
complex
consist
larg
polymeras
protein
l
cofactor
phosphoprotein
p
n
p
l
suffici
mediat
viral
replic
transcript
activ
also
requir
protein
function
polymeras
process
cofactor
featur
mononegaviral
rdrp
present
viru
particl
initi
viral
mrna
transcript
upon
releas
rnp
cytoplasm
order
gene
along
genom
hrsv
nonstructur
protein
n
p
matrix
small
hydrophob
sh
glycoprotein
g
fusion
f
l
synthesi
hrsv
mrna
propos
follow
transcript
gradient
gene
end
genom
eg
transcrib
gene
end
genom
eg
l
gene
thu
provid
control
viral
protein
abund
macrophag
epitheli
cell
involv
innat
immun
respons
hrsv
mani
cytokin
chemokin
includ
tnf
ifn
produc
cell
type
respons
hrsv
infect
detect
enhanc
amount
respiratori
secret
children
hospit
hrsv
infect
hrsv
infect
cell
antivir
signal
pathway
activ
eg
refer
depend
genotyp
viru
howev
hrsv
protein
also
modul
host
respons
infect
protein
inhibit
ifn
regulatori
factor
activ
modul
type
ifn
induc
signal
effect
host
cell
biolog
hrsv
also
regul
product
function
ifn
inhibit
tolllik
receptor
tlr
signal
mitochondri
antivir
signal
protein
moreov
reduc
apoptosi
enhanc
surviv
infect
cell
result
activ
phosphoinositidid
pathway
solubl
factor
releas
supernat
infect
cell
hrsv
infect
initi
strong
neutrophil
respons
associ
inflamm
follow
tcell
lymphopenia
pulmonari
tcell
respons
protect
antibodi
respons
associ
bcell
stimul
factor
immun
reinfect
complet
may
part
due
abil
viru
interfer
antibodi
induc
neutral
whilst
mani
studi
focus
interact
hrsv
host
cell
want
use
high
resolut
approach
character
hrsv
infect
vivo
given
hrsv
predominantli
childhood
infect
want
explor
effect
viru
popul
ethic
practic
difficult
take
lung
biopsi
patient
group
particularli
control
group
obviou
sign
ill
instead
diagnost
left
nasopharyng
aspir
use
proxi
high
resolut
approach
identifi
molecular
chang
respiratori
tract
result
viru
infect
two
high
resolut
approach
use
quantit
proteom
use
liquid
chromatographi
tandem
mass
spectrometri
lcmsm
rna
sequenc
rnaseq
illumina
techniqu
provid
inform
viral
cellular
protein
mrna
vari
hrsvinfect
uninfect
children
nasopharyng
aspir
collect
hrsv
subgroup
posit
children
yearsold
median
age
iqr
admit
great
ormond
street
hospit
children
london
uk
hrsv
diagnosi
confirm
film
array
multiplex
polymeras
chain
reaction
pcr
system
respiratori
panel
biomerieux
diagnost
panel
detect
common
respiratori
pathogen
adenoviru
coronaviru
coronaviru
coronaviru
human
metapneumoviru
human
rhinovirusenteroviru
influenza
influenza
influenza
influenza
influenza
b
parainfluenza
viru
parainfluenza
viru
parainfluenza
viru
parainfluenza
viru
hrsv
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
studi
nasopharyng
aspir
repres
discard
nh
leftov
sampl
identifi
inform
nasopharyng
aspir
sampl
hrsvneg
children
similar
age
yearsold
median
age
iqr
obtain
hrsv
season
use
control
pathogen
detect
group
use
film
array
nasopharyng
aspir
sampl
carri
per
hospit
guidelin
briefli
cathet
insert
nose
direct
posteriorli
toward
open
extern
ear
order
reach
posterior
pharynx
suction
appli
cathet
slowli
withdrawn
use
rotat
movement
remain
less
nasopharynx
cathet
rins
small
volum
steril
salin
solut
ensur
adequ
specimen
volum
sampl
store
c
use
cell
kindli
provid
ralph
tripp
univers
georgia
grown
c
dulbecco
modifi
eagl
medium
dmem
high
glucos
gl
life
technolog
grand
island
new
york
usa
supplement
vv
fb
penicillin
iuml
streptomycin
pen
strep
life
technolog
renfrew
uk
commerci
avail
primari
pediatr
bronchial
epitheli
cell
donor
age
year
lonza
basel
switzerland
grown
transwel
corn
new
york
usa
mm
diamet
pore
size
initi
airliquid
interfac
cultur
basolater
medium
promocel
heidelberg
germani
replac
fresh
medium
liquid
mucu
apic
surfac
aspir
everi
day
apic
side
wash
prior
infect
serum
free
sf
dmem
addit
viru
stock
cell
line
confirm
mycoplasmafre
use
lookout
mycoplasma
pcr
detect
kit
ali
cultur
donor
infect
hrsv
multipl
infect
moi
use
sfdmem
addit
treat
cell
mock
infect
calcul
moi
cultur
one
well
donor
trypsin
enumer
infect
apic
side
wash
twice
sfdmem
addit
fresh
medium
ad
basolater
side
cultur
infect
apic
side
ali
incub
h
c
viru
stock
dilut
sfdmem
addit
beforehand
medium
mock
subsequ
viru
inoculum
remov
apic
side
rins
time
sfdmem
addit
cultur
kept
c
monitor
daili
light
microscopi
cpe
sampl
prepar
mass
spectrometri
analysi
adapt
approach
describ
previous
solubl
protein
precipit
addit
icecold
wv
trichloroacet
acid
tca
final
concentr
wv
incub
ice
h
sampl
centrifug
g
min
pellet
protein
pellet
wash
three
time
icecold
aceton
allow
air
dri
protein
pellet
resolubilis
mm
ammonium
bicarbon
rapigest
water
manchest
uk
protein
concentr
determin
use
pierc
coomassi
plu
bradford
protein
assay
fisher
scientif
loughborough
uk
follow
manufactur
instruct
sampl
protein
content
volum
normal
mm
ammonium
bicarbon
sampl
heat
c
min
reduc
mm
dithiothreitol
sigmaaldrich
compani
ltd
gillingham
uk
c
min
alkyl
mm
iodoacetimd
sigma
room
temperatur
min
dark
proteom
grade
trypsin
sigma
ad
protein
trypsin
ratio
sampl
incub
c
overnight
rapigest
remov
ad
tfa
final
concentr
vv
incub
c
h
peptid
sampl
centrifug
g
min
c
remov
precipit
rapigest
sampl
desalt
use
spin
tip
pierc
fisher
scientif
loughborough
uk
accord
manufactur
instruct
peptid
analyz
onlin
nanoflow
lcmsm
peptid
separ
use
ultim
nano
system
dionexthermo
fisher
scientif
equip
easyspray
pepmap
rslc
analyt
column
cm
inner
diamet
fuse
silica
nanoelectrospray
emitt
dionex
thermoscientif
hemel
hempstead
uk
column
kept
c
chromatographi
perform
buffer
system
consist
formic
acid
buffer
acetonitril
formic
acid
buffer
b
peptid
separ
linear
gradient
buffer
b
min
flow
rate
nlmin
lc
system
coupl
qexact
mass
spectromet
thermo
fisher
scientif
mass
spectromet
oper
datadepend
mode
survey
scan
acquir
resolut
mz
scan
rang
mz
top
abund
isotop
pattern
charg
state
survey
scan
select
isol
window
th
fragment
higher
energi
collision
dissoci
normal
collis
energi
maximum
ion
inject
time
survey
scan
msm
scan
ms
respect
ion
target
valu
set
survey
scan
msm
scan
msm
event
acquir
resolut
repetit
sequenc
peptid
minim
dynam
exclus
sequenc
peptid
thermo
raw
file
import
progenesi
qi
proteom
version
nonlinear
dynam
newcastl
upon
tyne
uk
peak
pick
softwar
use
default
set
filter
includ
peak
charg
state
spectral
data
convert
mgf
file
progenesi
lcm
export
peptid
identif
use
mascot
version
matrix
scienc
london
uk
search
engin
tandem
ms
data
search
human
hrsv
b
databas
uniprot
feb
sequenc
residu
search
paramet
follow
precursor
mass
toler
set
ppm
fragment
mass
toler
set
da
two
miss
tryptic
cleavag
permit
carbamidomethyl
cystein
set
fix
modif
oxid
methionin
set
variabl
modif
mascot
search
result
valid
use
machin
learn
algorithm
percol
embed
within
mascot
mascot
decoy
databas
function
util
fals
discoveri
rate
individu
percol
ion
score
indic
ident
extens
homolog
p
mascot
search
result
import
progenesi
lcm
xml
file
rel
protein
abund
calcul
default
method
within
progenesi
total
rna
extract
clinic
nasopharyng
aspir
triplic
use
qiagen
rneasi
minikit
rna
concentr
measur
qubit
rna
br
assay
agaros
gel
electrophoresi
ethidium
bromid
etbr
stain
use
visual
rna
order
check
qualiti
rna
sampl
cdna
synthes
rna
via
revers
transcript
order
check
amplif
use
rdrp
chain
reaction
sampl
qualiti
check
integr
bioanalyz
rna
picochip
quantiti
qubit
rna
kit
invitrogen
life
technolog
ltd
paisley
uk
assess
rna
qualiti
good
rna
integr
number
rin
valu
sampl
subject
poli
select
use
dynabead
mrna
purif
kit
invitrogen
life
technolog
ltd
paisley
uk
case
bead
per
sampl
wash
bind
buffer
resuspend
bead
buffer
sampl
made
heat
c
min
remov
secondari
structur
sampl
mix
bead
rotat
min
room
temperatur
collect
bead
magnet
particl
concentr
mpc
bead
wash
twice
wash
buffer
remov
trace
wash
step
twelv
microlit
water
ad
bead
elut
achiev
heat
sampl
c
min
retriev
supernat
contain
rna
assess
rrna
rna
picochip
twiceselect
materi
use
input
scriptseq
assay
epicentr
madison
usa
sampl
treat
per
manufactur
protocol
sampl
mix
primer
fragment
buffer
heat
c
min
place
ice
sampl
convert
cdna
purifi
ampur
xp
sampl
mix
barcod
primer
amplifi
pcr
cycl
librari
purifi
ampur
xp
assess
use
bioanalyz
hs
dna
kit
quantiti
determin
use
qubit
dna
hs
kit
sampl
pool
equimolar
basi
singl
lane
quantiti
qualiti
final
pool
assess
use
qubit
kit
invitrogen
life
technolog
ltd
paisley
uk
bioanalyz
agil
cheshir
uk
quantit
pcr
use
kapa
librari
quantif
kit
roch
light
cycler
machin
accord
manufactur
instruct
templat
dna
denatur
accord
protocol
describ
illumina
cbot
user
guid
load
pm
improv
sequenc
qualiti
control
spike
sampl
sequenc
carri
illumina
hiseq
instrument
version
chemistri
gener
pairedend
read
time
point
sequenc
read
map
genom
use
align
hrsv
genom
output
bam
file
analyz
use
quasirecomb
align
million
read
hrsv
genom
select
million
align
random
use
coverag
option
quasirecomb
command
line
java
xx
newratio
jar
quasirecombjar
readssam
coverag
pars
output
file
inhous
softwar
written
perl
determin
abund
nucleotid
posit
ie
consensu
nucleotid
report
frequenc
use
three
nucleotid
describ
previous
hrsv
infect
result
sever
infect
children
requir
hospit
investig
effect
hrsv
infect
patient
group
nasopharyng
aspir
taken
routin
diagnost
purpos
analyz
use
quantit
proteom
rnaseq
data
also
compar
analysi
nasopharyng
aspir
taken
control
group
children
neg
time
sampl
hrsv
children
infect
hrsv
sampl
analyz
children
differ
viral
load
time
sampl
group
three
arbitrari
categori
low
viral
load
ct
n
medium
viral
load
ct
n
high
viral
load
ct
n
hrsv
respiratori
pathogen
identifi
clinic
set
use
multiplex
rtpcr
respiratori
pathogen
screen
panel
proteom
propos
use
potenti
identif
pathogen
complex
sampl
howev
nucleic
acidbas
approach
sequenc
search
paramet
must
contain
inform
eg
amino
acid
sequenc
pathogen
search
convent
nucleic
acidbas
detect
system
thought
sensit
proteinbas
assay
evalu
lcmsm
use
identifi
hrsv
protein
nasopharyng
aspir
sampl
would
predict
viral
protein
present
virion
would
predomin
viral
protein
present
intracellularli
nasopharyng
aspir
main
repres
secret
respiratori
epithelia
total
five
viral
protein
identifi
quantifi
use
two
peptid
figur
n
peptid
f
peptid
peptid
p
peptid
peptid
addit
three
viral
protein
identifi
singl
uniqu
peptid
l
therefor
could
quantifi
peptid
abund
profil
also
correl
viral
load
eg
viral
protein
abund
highest
viral
load
least
abund
lowest
viral
load
see
supplement
tabl
anova
comparison
two
hrsv
protein
detect
g
protein
even
though
protein
encod
transcript
higher
predict
abund
f
l
transcript
g
protein
present
virion
major
identifi
viral
protein
consist
presenc
viru
particl
nasopharyng
aspir
rather
protein
intracellular
materi
exampl
protein
identifi
virus
x
peer
review
abund
f
l
transcript
g
protein
present
virion
major
identifi
viral
protein
consist
presenc
viru
particl
nasopharyng
aspir
rather
protein
intracellular
materi
exampl
protein
identifi
hrsv
shown
exhibit
genom
divers
patient
isol
particularli
g
gene
data
suggest
mean
rate
nucleotid
substitut
approxim
per
site
per
year
investig
viral
genom
minor
variant
present
viral
genom
patient
rnaseq
use
sequenc
viral
rna
present
within
nasopharyng
aspir
suffici
read
depth
consensu
genom
minor
variant
analysi
obtain
three
patient
two
ct
valu
term
one
ct
valu
term
figur
would
predict
data
indic
read
map
viral
genom
two
sampl
highest
viral
load
compar
sampl
lower
viral
load
gene
low
medium
high
hrsv
shown
exhibit
genom
divers
patient
isol
particularli
g
gene
data
suggest
mean
rate
nucleotid
substitut
approxim
per
site
per
year
investig
viral
genom
minor
variant
present
viral
genom
patient
rnaseq
use
sequenc
viral
rna
present
within
nasopharyng
aspir
suffici
read
depth
consensu
genom
minor
variant
analysi
obtain
three
patient
two
ct
valu
term
one
ct
valu
term
figur
would
predict
data
indic
read
map
viral
genom
two
sampl
highest
viral
load
compar
sampl
lower
viral
load
although
peak
trough
read
map
genom
gener
number
map
read
equival
across
genom
apart
termini
figur
would
consist
nasopharyng
aspir
contain
viral
particl
rather
intracellular
materi
latter
case
would
predict
observ
mark
decreas
abund
l
mrna
least
abund
viral
mrna
express
cell
cultur
first
sequenc
read
depth
would
predict
follow
transcript
gradient
viral
mrna
synthesi
second
decreas
read
map
intergen
region
compar
proxim
encod
mrna
viral
mrna
present
read
map
intergen
region
would
predict
underrepres
case
map
read
use
assembl
consensu
genom
viru
within
patient
also
determin
whether
minor
variant
exist
three
assembl
consensu
genom
compar
previou
hrsv
strain
map
subgroup
virus
figur
although
peak
trough
read
map
genom
gener
number
map
read
equival
across
genom
apart
termini
figur
would
consist
nasopharyng
aspir
contain
viral
particl
rather
intracellular
materi
latter
case
would
predict
observ
mark
decreas
abund
l
mrna
least
abund
viral
mrna
express
cell
cultur
first
sequenc
read
depth
would
predict
follow
transcript
gradient
viral
mrna
synthesi
second
decreas
read
map
intergen
region
compar
proxim
encod
mrna
viral
mrna
present
read
map
intergen
region
would
predict
underrepres
case
map
read
use
assembl
consensu
genom
viru
within
patient
also
determin
whether
minor
variant
exist
three
assembl
consensu
genom
compar
previou
hrsv
strain
map
subgroup
virus
figur
whilst
phylogenet
use
compar
viral
genotyp
sampl
due
error
prone
natur
rna
depend
rna
polymeras
mutat
also
occur
viru
replic
lead
genom
divers
within
particularli
patient
variou
select
pressur
antibodi
respons
act
genom
time
lead
emergenceselect
specif
mutat
rnaseq
data
use
captur
inform
viral
genom
variat
within
patient
genom
variat
captur
minor
variant
frequenc
variant
reach
threshold
becom
part
consensu
genom
sequenc
assembl
map
minor
variant
abl
examin
nucleotid
variat
within
viral
genom
obtain
three
clinic
sampl
refer
genom
variat
compar
hrsv
strain
grown
air
liquid
interfac
cultur
triplic
also
use
publish
dataset
work
examin
genom
variabl
hrsv
cell
cultur
cell
air
liquid
interfac
ali
cultur
system
recapitul
major
aspect
respiratori
epithelia
absenc
adapt
respons
strain
use
laboratori
adapt
strain
undergo
product
replic
cell
ali
cultur
system
three
clinic
isol
indic
arrow
group
b
refer
full
genom
sequenc
genebank
databas
neighborjoiningkimura
twoparamet
phylogenet
analysi
perform
use
softwar
packag
data
indic
three
sampl
sequenc
contain
hrsv
similar
isol
whilst
phylogenet
use
compar
viral
genotyp
sampl
due
error
prone
natur
rna
depend
rna
polymeras
mutat
also
occur
viru
replic
lead
genom
divers
within
particularli
patient
variou
select
pressur
antibodi
respons
act
genom
time
lead
emergenceselect
specif
mutat
rnaseq
data
use
captur
inform
viral
genom
variat
within
patient
genom
variat
captur
minor
variant
frequenc
variant
reach
threshold
becom
part
consensu
genom
sequenc
assembl
map
minor
variant
abl
examin
nucleotid
variat
within
viral
genom
obtain
three
clinic
sampl
refer
genom
variat
compar
hrsv
strain
grown
air
liquid
interfac
cultur
triplic
also
use
publish
dataset
work
examin
genom
variabl
hrsv
cell
cultur
cell
air
liquid
interfac
ali
cultur
system
recapitul
major
aspect
respiratori
epithelia
absenc
adapt
respons
strain
use
laboratori
adapt
strain
undergo
product
replic
cell
ali
cultur
system
data
indic
clinic
sampl
transit
substitut
significantli
higher
frequenc
transvers
substitut
p
figur
overal
total
frequenc
minor
variant
observ
viral
genom
sequenc
clinic
sampl
less
viru
grown
either
air
liquid
interfac
cultur
cell
cultur
figur
analysi
indic
variat
occur
uniformli
across
genom
instead
local
mani
case
discret
cluster
figur
previous
observ
viru
grown
cell
cultur
part
data
previou
studi
includ
comparison
interestingli
cluster
variat
appear
nonrandom
group
togeth
viru
isol
nasopharyng
aspir
air
liquid
interfac
cultur
cell
cultur
figur
reflect
greater
nucleotid
variat
cell
cultur
deriv
viru
compar
viru
deriv
air
liquid
interfac
nasopharyng
aspir
figur
appear
greater
frequenc
variat
cluster
cell
cultur
deriv
viru
compar
either
viru
found
ali
nasopharyng
aspir
clinic
would
indic
ali
may
recapitul
viral
replicationselect
observ
vivo
hotspot
transit
transvers
substitut
appear
across
genom
exampl
occurr
shown
g
f
l
gene
figur
transit
transvers
analys
condit
analysi
implement
use
slide
window
across
hrsv
genom
box
plot
indic
mean
valu
percentil
confid
interv
ci
mean
analysi
also
perform
use
slide
window
result
similar
cell
air
liquid
interfac
ali
clinic
sampl
cl
refer
viral
rna
sequenc
cell
cultur
air
liquid
interfac
sampl
clinic
sampl
statist
signific
estim
use
kruskalw
signific
threshold
p
data
indic
clinic
sampl
transit
substitut
significantli
higher
frequenc
transvers
substitut
p
figur
overal
total
frequenc
minor
variant
observ
viral
genom
sequenc
clinic
sampl
less
viru
grown
either
air
liquid
interfac
cultur
cell
cultur
figur
analysi
indic
variat
occur
uniformli
across
genom
instead
local
mani
case
discret
cluster
figur
previous
observ
viru
grown
cell
cultur
part
data
previou
studi
includ
comparison
interestingli
cluster
variat
appear
nonrandom
group
togeth
viru
isol
nasopharyng
aspir
air
liquid
interfac
cultur
cell
cultur
figur
reflect
greater
nucleotid
variat
cell
cultur
deriv
viru
compar
viru
deriv
air
liquid
interfac
nasopharyng
aspir
figur
appear
greater
frequenc
variat
cluster
cell
cultur
deriv
viru
compar
either
viru
found
ali
nasopharyng
aspir
clinic
would
indic
ali
may
recapitul
viral
replicationselect
observ
vivo
hotspot
transit
transvers
substitut
appear
across
genom
exampl
occurr
shown
g
f
l
gene
figur
sequenc
data
demonstr
variabl
g
gene
sequenc
differ
hrsv
strain
highli
variabl
region
identifi
geneprotein
may
result
antigen
variabl
viru
whilst
variabl
identifi
differ
viru
isol
whether
nucleotid
variabl
occur
within
patient
unknown
sequenc
data
demonstr
variabl
g
gene
sequenc
differ
hrsv
strain
highli
variabl
region
identifi
geneprotein
may
result
antigen
variabl
viru
whilst
variabl
identifi
differ
viru
isol
whether
nucleotid
variabl
occur
within
patient
unknown
assembl
minor
variant
consensu
genom
abl
examin
within
patient
variat
nucleotid
sequenc
figur
data
indic
differ
minor
variant
patient
viral
genom
within
nasopharyng
aspiratepati
distinct
cluster
variant
along
genom
observ
particularli
glycoprotein
code
region
suggest
underli
variabl
region
even
within
patient
numer
studi
suggest
sequala
infect
hrsv
associ
initi
innat
immun
respons
data
support
obtain
vivo
sampl
vivo
model
ex
vivo
sampl
cell
cultur
hrsv
encod
sever
protein
includ
protein
associ
host
cell
protein
modul
innat
respons
host
pathway
investig
host
respons
clinic
nasopharyng
aspir
sampl
mass
spectrometri
follow
progenesi
analysi
use
identifi
quantifi
cellular
protein
data
visual
form
heat
map
cluster
chang
abund
cellular
protein
accord
whether
sampl
came
uninfect
infect
children
sampl
infect
children
classifi
categori
viral
load
low
infect
ct
score
medium
ct
score
high
ct
score
therefor
analysi
indic
proteom
nasopharyng
aspir
differ
differ
infect
group
control
group
indic
defin
cellular
protein
either
increas
decreas
abund
nasopharyng
aspir
infect
children
compar
control
nonhrsv
children
also
depend
viral
load
protein
greater
abund
proteom
nasopharyng
aspir
sampl
infect
children
compar
control
children
includ
exampl
protein
encod
interferon
stimul
gene
eg
particular
interest
mucin
eg
mucb
bpi
protein
member
latter
protein
implic
antivir
respons
influenza
viru
shown
characterist
inflammatori
lung
diseas
numer
studi
suggest
sequala
infect
hrsv
associ
initi
innat
immun
respons
data
support
obtain
vivo
sampl
vivo
model
ex
vivo
sampl
cell
cultur
hrsv
encod
sever
protein
includ
protein
associ
host
cell
protein
modul
innat
respons
host
pathway
investig
host
respons
clinic
nasopharyng
aspir
sampl
mass
spectrometri
follow
progenesi
analysi
use
identifi
quantifi
cellular
protein
data
visual
form
heat
map
cluster
chang
abund
cellular
protein
accord
whether
sampl
came
uninfect
infect
children
sampl
infect
children
classifi
categori
viral
load
low
infect
ct
score
medium
ct
score
high
ct
score
therefor
analysi
indic
proteom
nasopharyng
aspir
differ
differ
infect
group
control
group
indic
defin
cellular
protein
either
increas
decreas
abund
nasopharyng
aspir
infect
children
compar
control
nonhrsv
children
also
depend
viral
load
protein
greater
abund
proteom
nasopharyng
aspir
sampl
infect
children
compar
control
children
includ
exampl
protein
encod
interferon
stimul
gene
eg
particular
interest
mucin
eg
mucb
bpi
protein
member
latter
protein
implic
antivir
respons
influenza
viru
shown
characterist
inflammatori
lung
diseas
hrsv
infect
caus
mild
diseas
children
caus
sever
diseas
children
requir
hospit
particularli
children
decreas
lung
function
underli
health
complic
much
diseas
associ
hrsv
infect
propos
host
mediat
highest
viral
load
often
time
maximum
ill
studi
hrsv
infect
lung
complic
invas
sampl
procedur
requir
access
organ
particularli
children
inform
consent
directli
obtain
child
instead
proxi
tool
air
liquid
interfac
sampl
secret
lung
provid
next
best
solut
latter
case
either
nasal
swab
nasopharyng
aspir
provid
indic
form
cellular
protein
may
associ
infect
differ
nasal
swab
nasopharyng
aspir
nasal
swab
obtain
insert
tip
bulb
nostril
nasopharyng
aspir
requir
suction
devic
sampl
deepli
children
hrsv
nasopharyng
aspir
use
detect
hrsv
nasal
swab
use
studi
herein
evalu
hrsv
viral
load
studi
host
respons
achiev
combin
highresolut
sequenc
proteom
identif
pathogen
sampl
patient
reli
techniqu
microscopi
antigensantibodi
nucleic
acidbas
approach
pcrrtpcr
recent
mass
spectrometri
base
approach
propos
disrupt
technolog
identifi
pathogen
use
identifi
bacteria
commun
death
ebola
viru
diseas
studi
lcmsm
identifi
peptid
hrsv
protein
nasopharyng
aspir
children
figur
confirm
hrsv
infect
use
nucleic
acidbas
approach
two
hrsv
protein
g
identifi
lcmsm
even
though
would
predict
higher
abund
protein
encod
downstream
transcript
particularli
g
protein
observ
previou
studi
may
indic
g
proteinpeptid
hard
identifi
lcmsm
indic
protein
stabil
nevertheless
gener
data
support
propos
ms
base
approach
use
identifi
pathogen
biolog
relev
materi
exampl
matrix
assist
laser
desorptionion
time
flight
mass
spectrometri
malditof
ms
use
identifi
bacteri
viral
pathogen
clinic
sampl
rnaseq
analysi
nasopharyng
aspir
also
identifi
hrsv
nucleic
de
novo
assembl
phylogenet
analysi
demonstr
viru
present
nasopharyng
aspir
close
map
subgroup
viru
metagenom
analysi
indic
nucleic
acid
virus
reach
threshold
level
signific
therefor
confirm
find
respiratori
array
rnaseq
analysi
minor
variant
hrsv
genom
indic
variant
occur
discret
cluster
along
genom
figur
previou
work
shown
ribavirin
therapeut
treatment
hrsv
induc
hypermut
along
genom
lead
error
catastroph
concomit
reduct
viral
load
rnaseq
data
indic
whilst
minor
variant
occur
cluster
along
genom
increas
frequenc
cell
cultur
model
infect
compar
authent
airliquid
interfac
cultur
system
nasopharyng
aspir
figur
may
due
greater
select
pressur
ex
vivo
vivo
system
compar
cell
cultur
grown
viru
cluster
minor
variant
may
implic
provid
nois
select
work
upon
also
may
result
aberr
viral
protein
present
minor
level
nevertheless
observ
suggest
use
continu
cell
cultur
studi
viru
evolut
may
entir
best
model
relat
observ
larg
degre
variabl
g
gene
hrsv
g
protein
involv
receptor
recognit
one
major
antigen
determin
reason
propos
exhibit
high
degre
antigen
divers
gener
antibodi
escap
mutant
data
suggest
mechan
oper
within
patient
infect
quantit
proteom
analysi
also
identifi
cellular
protein
nasopharyng
aspir
abund
protein
chang
abund
sampl
taken
children
infect
hrsv
compar
hrsvneg
children
figur
increas
protein
abund
exampl
link
viral
load
unsurprisingli
suggest
host
respons
vari
accord
amount
viru
interest
identif
sever
protein
increas
abund
hrsvinfect
children
belong
mucin
bpicontain
protein
latter
antivir
properti
exampl
deplet
shown
enhanc
coxsackieviru
b
cvb
replic
bpi
l
level
also
associ
acut
pneumonia
adult
proteom
analysi
show
sever
cellular
protein
associ
hrsv
viru
particl
suggest
function
relev
potenti
therapeut
target
inde
inhibit
small
molecul
advers
effect
hrsv
biolog
proteom
analysi
bronchoalveolar
lavag
calv
infect
bovin
rsv
suggest
activ
neutrophil
antioxid
treatment
consid
mitig
physiolog
effect
infect
hrsv
infect
caus
mild
diseas
children
caus
sever
diseas
children
requir
hospit
particularli
children
decreas
lung
function
underli
health
complic
much
diseas
associ
hrsv
infect
overal
proteom
character
nasopharyng
aspir
hrsvinfect
children
may
identifi
potenti
antivir
molecul
protein
involv
control
secretori
pathway
traffick
may
provid
target
therapeut
intervent
potenti
biomark
point
care
diagnost
assess
sever
infect
guid
clinic
intervent
